Rituximab: Mechanisms and applications

British Journal of Cancer

Volumn 85, Issue 11, 2001, Pages 1619-1623

  Johnson, P W M ^a   Glennie, M J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, B-CELL; TREATMENT OUTCOME;

EID: 0035977173     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2127     Document Type: Review

References (50)

1. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs
2. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis
3. 2+ conductance found constitutively in B lymphocytes
4. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
5. Protein lipidation in cell signaling
6. Fc receptors are required in passive and active immunity to melanoma
7. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
8. Rituximab (anti-CD20 monoclonai antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
9. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
10. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
11. Signaling antibodies in cancer therapy
12. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
13. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
14. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of retreatment
15. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn. Fyn and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20
16. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment
17. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
18. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
19. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
20. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
21. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin
22. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-raediated cell lysis
23. The CD20 (Bp35) antigen is involved in activation of B cells from the GO to the G1 phase of the cell cycle
24. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
25. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms
26. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine
27. Variability of polymerase chain reaction detection of the Bcl2-IgH translocation in an International multicentre study
28. Transmembrane signals generated through MHC class II. CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway
29. Expression of calcium-permeable cation channel CD20 accelerates progression through the Gl phase in Ba1b/c 3T3 cells
30. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
31. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion
32. Anti-CD20-and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways
33. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
34. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
35. Rituximab dose-escalation trial in chronic lymphocytic leukemia
36. Mice carrying a CD20 gene disruption
37. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment
38. Monoclonal antibody I F5 (anti-CD20) serotherapy of human B cell lymphomas
39. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia
40. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
41. The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate
42. Characterization of a human B lymphocyte-specific antigen
43. Supramolecular complexes of MHC class I. MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY
44. Phosphorylation of the Bl (CD20) molecule by normal and malignant human B lymphocytes
45. CD20: A regulator of cell-cycle progression of B lymphocytes
46. Monoclonal antibodies as agonists: An expanded role for their use in cancer therapy
47. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
48. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma
49. Final results of a randomized controlled study of the Zevalin™ radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL
50. Efficacy of rituximab in hairy cell leukemia treatment